Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib versus placebo after chemotherapy for progressing oesophageal cancer
ISRCTN29580179Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Mar 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of gefitinib in esophageal cancer, sponsored by University of Oxford. Primary endpoint: Overall survival. Started Mar 2009; status: completed.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ISRCTN29580179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29580179.